Janssen Vaccines

Formerly| Crucell
Type| Subsidiary
Industry| Biotechnology
Founded| 2000; 26 years ago (2000)
Headquarters| Archimedesweg 4,

Leiden

Netherlands

Key people

* Ronald Brus (CEO)
* Jan Pieter Oosterveld (chairman of the supervisory board)

Products| Vaccines and antibodies
Parent| Johnson & Johnson

Janssen Vaccines, formerly Crucell, is a biotechnology company specializing in vaccines and biopharmaceutical technologies. It was formed when Johnson & Johnson acquired the Dutch biotech company Crucell. Janssen Vaccines is part of Johnson & Johnson Innovative Medicine business segment.

## Contents

* 1 History
* 1.1 COVID-19 vaccine development
* 2 References

## History

In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.[1][2]

In September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine.[3] This followed Crucell's discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses. J&J acquired the rest of the company in October 2010, taking its stake to over 95% by February 2011[4][5] and delisting the company from stock exchanges two months later.[6]

After the takeover by Johnson & Johnson in 2011, Crucell was assigned to Janssen Pharmaceuticals division. In 2014, the subsidiary was renamed from Crucell to Janssen Vaccines.[7][8]

### COVID-19 vaccine development

## References

1. ↑ "Press Release: Crucell Acquires SBL Vaccin AB | Fierce Biotech" (in en). www.fiercebiotech.com. 21 November 2006. https://www.fiercebiotech.com/biotech/press-release-crucell-acquires-sbl-vaccin-ab.
2. ↑ "Crucell to buy Berna Biotech - PharmaTimes". 2 December 2005. https://pharmatimes.com/news/crucell_to_buy_berna_biotech_997459/.
3. ↑ Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. https://www.reuters.com/article/rbssPharmaceuticals - Generic & Specialty/idUSLS21205620090928.
4. ↑ Solsman, Joan E. (17 February 2011). "J&J: Sufficient Number Of Crucell Holders Tender Shares". The Wall Street Journal. Dow Jones Newswires. https://www.wsj.com/article/BT-CO-20110217-717650.html.
5. ↑ "J&J aiming to buy vaccine maker Crucell for $2.3 billion" (in en). 17 September 2010. https://www.reuters.com/article/us-crucell/jj-aiming-to-buy-vaccine-maker-crucell-for-2-3-billion-idUSTRE68G0RX20100917.
6. ↑ Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. https://www.reuters.com/article/crucell-idUSLDE73A0FR20110411.
7. ↑ "Crucell". DevEx. 2015. https://www.devex.com/organizations/crucell-44661.
8. ↑ "Janssen Vaccines AG". Company Profiles. Bloomberg. 2020. https://www.bloomberg.com/profile/company/0836856D:SW.

Template:Johnson & Johnson

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Janssen Vaccines. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Janssen_Vaccines&oldid=4175120"